AnaptysBio Long Term Debt 2014-2021 | ANAB

AnaptysBio long term debt from 2014 to 2021. Long term debt can be defined as the sum of all long term debt fields.
AnaptysBio Annual Long Term Debt
(Millions of US $)
2020 $
2019 $
2018 $
2017 $8
2016 $14
2015 $5
2014 $5
2013 $
AnaptysBio Quarterly Long Term Debt
(Millions of US $)
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30 $2
2018-06-30 $4
2018-03-31 $6
2017-12-31 $8
2017-09-30 $9
2017-06-30 $11
2017-03-31 $13
2016-12-31 $14
2016-09-30
2016-06-30
2016-03-31
2015-12-31 $5
2014-12-31 $5
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.787B $0.075B
AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00